Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice - PubMed (original) (raw)
Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice
Christina A Pacak et al. Genet Vaccines Ther. 2008.
Abstract
The AAV9 capsid displays a high natural affinity for the heart following a single intravenous (IV) administration in both newborn and adult mice. It also results in substantial albeit relatively lower expression levels in many other tissues. To increase the overall safety of this gene delivery method we sought to identify which one of a group of promoters is able to confer the highest level of cardiac specific expression and concurrently, which is able to provide a broad biodistribution of expression across both cardiac and skeletal muscle. The in vivo behavior of five different promoters was compared: CMV, desmin (Des), alpha-myosin heavy chain (alpha-MHC), myosin light chain 2 (MLC-2) and cardiac troponin C (cTnC). Following IV administration to newborn mice, LacZ expression was measured by enzyme activity assays. Results showed that rAAV2/9-mediated gene delivery using the alpha-MHC promoter is effective for focal transgene expression in the heart and the Des promoter is highly suitable for achieving gene expression in cardiac and skeletal muscle following systemic vector administration. Importantly, these promoters provide an added layer of control over transgene activity following systemic gene delivery.
Figures
Figure 1
A) Construct Diagrams. Promoters were switched into the backbone by replacement of the CMV promoter between the first NotI and AgeI sites. The Des construct was created using primers against human genomic DNA (forward [F] Des enhancer primer containing NotI) ATA AGA ATG CGG CCG CAC CCA TGC CTC CTC AGG TA, (reverse [R] Des enhancer primer containing XhoI) CCG CTC GAG GGT GGG GCC TCA AGT TTA T, ([F] Des promoter primer containing XhoI) CCG CTC GAG ATA ACC AGG GCT GAA AGA, ([R] Des promoter primer containing AgeI) TGTA CCG GTG ACG GCG CGG GCG AGG CT. The α-MHC construct was created by amplifying human genomic DNA: ([F] containing NotI) ATA AGA ATG CGG CCG CCC AGT TGT TCA ACT CAC CCT TCA and ([R] containing AgeI) TGT ACC GGT GGG TTG GAG AAA TCT CTG ACA GCT. The MLC-2 construct was created by replacing the backbone with the previously described rat MLC-2 promoter[20]. ([F] containing NotI) ATA AGA ATG CGG CCG CGA CCC AGA GCA CAG AGC ATC GT ([R] containing AgeI) TGT ACC GGT GAA TTC AAG GAG CCT GCT. The cTnC construct was created by amplifying human genomic DNA: ([F] containing Not1) ATA AGA ATG CGG CCG CCA GCC TGA GAT CAC TGG GAC CAG A ([R] containing Age1) TGT ACC GGT CCA TGC TGG CGG CTC ACA GGA. 5 × 1010vg/mouse was administered (n = 6 per promoter group) [23]. Tissue lysates were assayed using the Galacto-Star chemiluminescence reporter gene assay system (Tropix, Inc., Bedford, MA, USA). Protein concentrations were determined using the Bio-Rad DC protein assay kit (Bio-Rad, Hercules, CA, USA). B) β-galactosidase (β-gal) expression levels show that CMV provides the greatest amount of expression in the heart followed by Des and α-MHC. C) β-gal levels in skeletal muscle including the diaphragm were highest in mice that were administered the Des construct. (Di, diaphragm; Qu, quadriceps; So, soleus; ED, extensor digitorum longus; TA, tibialis anterior; Ga, gastrocnemius) D) Evaluation by β-gal assay of non-heart, non-skeletal muscle tissues revealed highest expression levels in brain and lung from mice injected with the Des construct. (Ht, heart; Br, brain; Lu, lung; Li, liver; Sp, spleen; Ki, kidney; SI, small intestine) E) and F) β-gal levels and biodistribution profiles from α-MHC and Des construct injected mice (respectively).
Similar articles
- A Calsequestrin Cis-Regulatory Motif Coupled to a Cardiac Troponin T Promoter Improves Cardiac Adeno-Associated Virus Serotype 9 Transduction Specificity.
Chamberlain K, Riyad JM, Garnett T, Kohlbrenner E, Mookerjee A, Elmastour F, Benard L, Chen J, VandenDriessche T, Chuah MK, Marian AJ, Hajjar RJ, Gurha P, Weber T. Chamberlain K, et al. Hum Gene Ther. 2018 Aug;29(8):927-937. doi: 10.1089/hum.2017.188. Epub 2018 May 9. Hum Gene Ther. 2018. PMID: 29641321 Free PMC article. - Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo.
Pacak CA, Mah CS, Thattaliyath BD, Conlon TJ, Lewis MA, Cloutier DE, Zolotukhin I, Tarantal AF, Byrne BJ. Pacak CA, et al. Circ Res. 2006 Aug 18;99(4):e3-9. doi: 10.1161/01.RES.0000237661.18885.f6. Epub 2006 Jul 27. Circ Res. 2006. PMID: 16873720 - Effect of heart ischemia and administration route on biodistribution and transduction efficiency of AAV9 vectors.
García-Olloqui P, Rodriguez-Madoz JR, Di Scala M, Abizanda G, Vales Á, Olagüe C, Iglesias-García O, Larequi E, Aguado-Alvaro LP, Ruiz-Villalba A, Prosper F, Gonzalez-Aseguinolaza G, Pelacho B. García-Olloqui P, et al. J Tissue Eng Regen Med. 2020 Jan;14(1):123-134. doi: 10.1002/term.2974. Epub 2019 Dec 22. J Tissue Eng Regen Med. 2020. PMID: 31677236 - microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors.
Geisler A, Jungmann A, Kurreck J, Poller W, Katus HA, Vetter R, Fechner H, Müller OJ. Geisler A, et al. Gene Ther. 2011 Feb;18(2):199-209. doi: 10.1038/gt.2010.141. Epub 2010 Nov 4. Gene Ther. 2011. PMID: 21048795 - Functions of myosin light chain-2 (MYL2) in cardiac muscle and disease.
Sheikh F, Lyon RC, Chen J. Sheikh F, et al. Gene. 2015 Sep 10;569(1):14-20. doi: 10.1016/j.gene.2015.06.027. Epub 2015 Jun 12. Gene. 2015. PMID: 26074085 Free PMC article. Review.
Cited by
- AAV-DJ is superior to AAV9 for targeting brain and spinal cord, and de-targeting liver across multiple delivery routes in mice.
Chauhan M, Daugherty AL, Khadir FE, Duzenli OF, Hoffman A, Tinklenberg JA, Kang PB, Aslanidi G, Pacak CA. Chauhan M, et al. J Transl Med. 2024 Sep 5;22(1):824. doi: 10.1186/s12967-024-05599-5. J Transl Med. 2024. PMID: 39237935 Free PMC article. - KCNQ1 suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome.
Bains S, Giammarino L, Nimani S, Alerni N, Tester DJ, Kim CSJ, Christoforou N, Louradour J, Horváth A, Beslac O, Barbieri M, Matas L, Hof TS, Lopez R, Perez-Feliz S, Parodi C, Garcia Casalta LG, Jurgensen J, Barry MA, Bego M, Keyes L, Owens J, Pinkstaff J, Koren G, Zehender M, Brunner M, Casoni D, Praz F, Haeberlin A, Brooks G, Ackerman MJ, Odening KE. Bains S, et al. Eur Heart J. 2024 Sep 29;45(36):3751-3763. doi: 10.1093/eurheartj/ehae476. Eur Heart J. 2024. PMID: 39115049 Free PMC article. - Strategies to improve safety profile of AAV vectors.
Suoranta T, Laham-Karam N, Ylä-Herttuala S. Suoranta T, et al. Front Mol Med. 2022 Nov 1;2:1054069. doi: 10.3389/fmmed.2022.1054069. eCollection 2022. Front Mol Med. 2022. PMID: 39086961 Free PMC article. Review. - Inhibition of miR-25 ameliorates cardiac and skeletal muscle dysfunction in aged mdx/utrn haploinsufficient (+/-) mice.
Kepreotis SV, Oh JG, Park M, Yoo J, Lee C, Mercola M, Hajjar RJ, Jeong D. Kepreotis SV, et al. Mol Ther Nucleic Acids. 2024 Mar 28;35(2):102174. doi: 10.1016/j.omtn.2024.102174. eCollection 2024 Jun 11. Mol Ther Nucleic Acids. 2024. PMID: 38584818 Free PMC article. - Transcriptional Targeting Approaches in Cardiac Gene Transfer Using AAV Vectors.
Schröder LC, Frank D, Müller OJ. Schröder LC, et al. Pathogens. 2023 Oct 30;12(11):1301. doi: 10.3390/pathogens12111301. Pathogens. 2023. PMID: 38003766 Free PMC article. Review.
References
- Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, Matelis LA, Kurtzman GJ, Byrne BJ. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA. 1996;93:14082–14087. doi: 10.1073/pnas.93.24.14082. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials